Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2008

View Archived Issues

Novel treatment options for obesity described in recent patents

Protein tyrosine phosphatase inhibition shows benefit in murine model of spinal cord injury

Prolonged survival following sorafenib treatment in hepatocellular carcinoma

Dynavax enters into supply and option agreement with Novartis for universal influenza vaccine

Shire launches Vyvanse for treatment of adults with ADHD

Reseachers report data on novel PET radioligand for mGluR5 imaging

Large study with IGIV-C reveals no effects in relapsing-remitting multiple sclerosis

Topigen completes enrollment in phase II clinical study of TPI-ASM-8 in asthma

sNDA submitted to FDA for Risperdal Consta Long-Acting Injection in bipolar disorder

Zelos receives regulatory approval from FDA and EMEA for phase III study of ZT-031

Cornerstone receives FDA approval to initiate phase I/II clinical trial of CPI-613 in cancer

European Commission grants approval to Merck Serono to broaden license for Erbitux

Progen terminates PI-88 phase III trial and provides strategy update

Novel oral BACE inhibitor reduces brain Abeta levels in monkeys

European Commission approves Apidra for treatment of children, adolescents with diabetes

CHMP issues positive opinion for Ceplene in acute myeloid leukemia

Amgen reports positive results from phase III trial of denosumab in osteoporosis

CHMP grants positive opinion to Omrix's Evicel human fibrin sealant for hemostasis

Xoma commences phase IIa XOMA-629 study in patients with impetigo

Novel HIV reverse transcriptase inhibitors named in recent Tibotec patent

New adenosine A2B receptor antagonists from Almirall

Paion doses first healthy volunteers in phase I CNS-7056 trial

Alizyme presents results from European phase III Colal-Pred trial

Biocompatibles to acquire BrachySciences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.